8-K ·Filed Jul 31, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001628280-26-051251
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Routine board appointment with no trading signal. Monitor for any future pipeline updates or financial disclosures, but this filing alone does not warrant a position change.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
VTGN ▲ +4.94% at T+20d
NEUTRAL call ✓ call won +4.94% · α vs SPY +1.95% · entry $0.2410 → $0.2529
Next anchor: T+60d in 24d
Latest observation: T+41 +115.78% FF3 residual α
Entry anchored
Jul 30, 03:59 PM ET
via exchange tick
T+1d
+1.66%
call +1.66% · α +0.24%
$0.2450
settled 2mo ago
T+5d
+19.34%
call +19.34% · α +15.82%
$0.2876
settled 8w ago
T+20d
+4.94%
call +4.94% · α +1.95%
$0.2529
settled 5w ago
T+60d
—
call — · α —
—
in 24d

Price Chart

Loading chart...

Executive Summary

Vistagen Therapeutics appointed Douglas J. Williamson, M.D. to its Board of Directors effective July 29, 2026. Dr. Williamson received stock options to purchase 40,826 shares at $0.2433 per share, vesting over three years. This is a routine board appointment with no material financial or operational impact.

Key Facts

  • Douglas J. Williamson, M.D. appointed to the Board of Directors on July 29, 2026.
  • Received options to purchase 40,826 shares of common stock at an exercise price of $0.2433 per share (closing price on appointment date).
  • Options vest in equal annual installments over three years, fully vested on the three-year anniversary.
  • Dr. Williamson also entitled to annual cash compensation and equity awards under the Director Compensation Plan.
  • Company entered into a standard Indemnification Agreement with Dr. Williamson.

Financial Impact

No material financial impact. The option grant is standard director compensation with a strike price at market.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-051251
Document: vtgn-20260729.htm0001628280-26-051251
Document: vtgn20260731ex991.htm0001628280-26-051251
Document: 0001628280-26-051251-index-headers.html0001628280-26-051251
Document: 0001628280-26-051251-index.html0001628280-26-051251
Document: 0001628280-26-051251.txt0001628280-26-051251
12 reports for VTGN
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+5▲ +20.40%Jun 11, 2026
Filters
Rows
Reports for VTGN — sortable, filterable
TypeNow
Aug 14, 2026
7w ago
8-K
BEARISH ★ 6/10
$0.2676 $0.2432▲ +9.12%▲ +7.13%$0.2847 (−6.39%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 4/10
$0.2676 $0.2432▼ −9.12%▼ −7.13%$0.2847 (+6.39%)
Jul 31, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$0.2410 $0.2529▲ +4.94%▲ +1.95%$0.2847 (+18.13%)
Jun 30, 2026
13w ago
8-K
BEARISH ★ 7/10
$0.2260 $0.2302▼ −1.86%▼ −2.89%$0.2847 (−25.97%)
Jun 17, 2026
15w ago
8-K
NEUTRAL ★ 2/10
$0.6702 $0.2400▼ −64.19%▼ −64.72%$0.2847 (−57.52%)
Jun 15, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$0.6900 $0.2461▼ −64.33%▼ −64.53%$0.2847 (−58.74%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 5/10
$0.5731 $0.2492▼ −56.52%▼ −58.41%$0.2847 (−50.32%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$0.5351 $0.2492▼ −53.43%▼ −57.05%$0.2847 (−46.79%)
May 19, 2026
19w ago
8-K
NEUTRAL ★ 4/10
$0.6400 $0.6702▲ +4.72%▲ +3.98%$0.2847 (−55.52%)
May 12, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$0.6200 $0.5400▼ −12.90%▼ −11.18%$0.2847 (−54.08%)
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access